79 related articles for article (PubMed ID: 27249762)
1. Real-World Conundrums and Biases in the Use of White Cell Growth Factors.
Smith TJ; Hillner BE
Am Soc Clin Oncol Educ Book; 2016; 35():e524-7. PubMed ID: 27249762
[TBL] [Abstract][Full Text] [Related]
2. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
3. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
4. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
5. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Weeks JA; Somerfield MR; Feinglass J; Smith TJ
J Clin Oncol; 1999 Nov; 17(11):3676-81. PubMed ID: 10550166
[TBL] [Abstract][Full Text] [Related]
6. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
7. [Primary lymphoma of the bladder: a case report].
Statoua M; Mokrim M; El Ghanmi J; Karmouni T; El Khadir K; Koutani A; Attya AI; Errihani H
Pan Afr Med J; 2014; 18():148. PubMed ID: 25419286
[TBL] [Abstract][Full Text] [Related]
8. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
9. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
10. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
Cancer Control; 2002; 9(3):203-11. PubMed ID: 12060818
[TBL] [Abstract][Full Text] [Related]
11. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Balducci L; Mo M; Abella E; Saven A
Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
[TBL] [Abstract][Full Text] [Related]
13. [Management of lymphoma with respect to pathologic classification: updates and controversies].
Zhu J; Song YQ
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):724-7. PubMed ID: 20079009
[No Abstract] [Full Text] [Related]
14. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
15. Treating chemotherapy induced agranulocytosis with granulocyte colony-stimulating factors in a patient on clozapine.
Kolli V; Denton K; Borra D; Pulluri M; Sharma A
Psychooncology; 2013 Jul; 22(7):1674-5. PubMed ID: 23059755
[TBL] [Abstract][Full Text] [Related]
16. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab.
Cheng C; Gallagher EM; Yeh JY; Earl MA
Anticancer Drugs; 2014 Sep; 25(8):964-9. PubMed ID: 24743519
[TBL] [Abstract][Full Text] [Related]
17. Dose-adjusted EPOCH-R for Burkitt lymphoma.
Hoelzer D
Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
[No Abstract] [Full Text] [Related]
18. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
19. Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.
Bozzoli V; Tisi MC; Maiolo E; Alma E; Bellesi S; D'Alo' F; Voso MT; Leone G; Hohaus S
Br J Haematol; 2015 Jun; 169(6):787-94. PubMed ID: 25819007
[TBL] [Abstract][Full Text] [Related]
20. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
